Targeting the indoleamine 2,3-dioxygenase pathway in cancer.
Targeting the indoleamine 2,3-dioxygenase pathway in cancer.
复制标题
DOI：
10.1186/s40425-015-0094-9
复制
发表时间：
2015
影响因子：
10.9
通讯作者：
Naing A
中科院分区：
文献类型：
--
作者：
Moon YW;Hajjar J;Hwu P;Naing A
肿瘤细胞通过称为免疫耐受性的过程逃脱了宿主的免疫监视系统。免疫疗法的靶向分子，这些分子是调节免疫反应的检查和平衡。吲哚胺-2,3-二加氧酶（IDO）是一种细胞内酶，通过色氨酸耗竭的过程，它具有免疫抑制作用，从而促进了肿瘤的免疫逃逸。这篇综述总结了我们当前对当前可用的IDO抑制剂以及正在临床开发的IDO抑制剂中IDO表达的知识。
Tumor cells escape the immune surveillance system of the host through a process called immune tolerance. Immunotherapy targets molecules that serve as checks and balances in the regulation of immune response. Indoleamine-2,3-dioxygenase (IDO) is an intracellular enzyme, which through the process of tryptophan depletion exerts an immunosuppressive effect, facilitating immune escape of tumors. This review summarizes our current knowledge on IDO expression in malignancies, the IDO inhibitors that are currently available and those under clinical development.